BRIEF-Ethyreal Bio Emerges From Stealth With $101 Million In Financing To Advance Ethy-001, A Potentially Best-In-Class Anti-Tshr Antibody For Thyroid Eye Disease And Graves’ Disease

June 10 (Reuters) -

  • ETHYREAL BIO EMERGES FROM STEALTH WITH $101 MILLION IN FINANCING TO ADVANCE ETHY-001, A POTENTIALLY BEST-IN-CLASS ANTI-TSHR ANTIBODY FOR THYROID EYE DISEASE AND GRAVES’ DISEASE

  • ETHYREAL BIO: SERIES A WAS CO-LED BY ATLAS VENTURE AND MEDICXI VENTURES, ALONGSIDE NANDI LIFE SCIENCES AND CHECKPOINT CAPITAL

  • ETHYREAL BIO: SERIES B INCLUDED ALL SERIES A INVESTORS AND WAS LED BY AVORO CAPITAL

Source text: ID:nGNX1B8G6h

Further company coverage: [ ]


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.